• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用发射α粒子的免疫偶联物进行放射免疫治疗。

Radioimmunotherapy with alpha-particle-emitting immunoconjugates.

作者信息

Macklis R M, Kinsey B M, Kassis A I, Ferrara J L, Atcher R W, Hines J J, Coleman C N, Adelstein S J, Burakoff S J

机构信息

Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115.

出版信息

Science. 1988 May 20;240(4855):1024-6. doi: 10.1126/science.2897133.

DOI:10.1126/science.2897133
PMID:2897133
Abstract

Alpha particles are energetic short-range ions whose higher linear energy transfer produces extreme cytotoxicity. An alpha-particle-emitting radioimmunoconjugate consisting of a bismuth-212-labeled monoclonal immunoglobulin M specific for the murine T cell/neuroectodermal surface antigen Thy 1.2 was prepared. Analysis in vitro showed that the radioimmunoconjugate was selectively cytotoxic to a Thy 1.2+ EL-4 murine tumor cell line. Approximately three bismuth-212-labeled immunoconjugates per target cell reduced the uptake of [3H]thymidine by the EL-4 target cells to background levels. Mice inoculated intraperitoneally with EL-4 cells were cured of their ascites after intraperitoneal injection of 150 microcuries of the antigen-specific radioimmunoconjugate, suggesting a possible role for such conjugates in intracavitary cancer therapy.

摘要

α粒子是具有高能量的短程离子,其较高的线性能量传递会产生极强的细胞毒性。制备了一种发射α粒子的放射免疫偶联物,它由针对小鼠T细胞/神经外胚层表面抗原Thy 1.2的铋-212标记的单克隆免疫球蛋白M组成。体外分析表明,该放射免疫偶联物对Thy 1.2+ EL-4小鼠肿瘤细胞系具有选择性细胞毒性。每个靶细胞大约三个铋-212标记的免疫偶联物可将EL-4靶细胞对[3H]胸腺嘧啶核苷的摄取降低至背景水平。腹腔注射EL-4细胞的小鼠在腹腔注射150微居里的抗原特异性放射免疫偶联物后,腹水得以治愈,这表明此类偶联物在腔内癌症治疗中可能具有一定作用。

相似文献

1
Radioimmunotherapy with alpha-particle-emitting immunoconjugates.使用发射α粒子的免疫偶联物进行放射免疫治疗。
Science. 1988 May 20;240(4855):1024-6. doi: 10.1126/science.2897133.
2
Alpha particle radio-immunotherapy: animal models and clinical prospects.α粒子放射免疫疗法:动物模型与临床前景。
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1377-87. doi: 10.1016/0360-3016(89)90938-3.
3
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.用针对前列腺特异性膜抗原的铋 - 213标记J591抗体对人前列腺癌进行体外和临床前靶向α治疗。
Prostate Cancer Prostatic Dis. 2002;5(1):36-46. doi: 10.1038/sj.pcan.4500543.
4
Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.α粒子放射免疫疗法的细胞动力学、剂量学和放射生物学:细胞凋亡的诱导
Radiat Res. 1992 May;130(2):220-6.
5
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.使用发射α粒子的放射免疫缀合物进行放射免疫治疗。
Acta Oncol. 1996;35(3):373-9. doi: 10.3109/02841869609101654.
6
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.用一种新型低剂量率发射α粒子的放射免疫偶联物进行靶向癌症治疗。
Blood. 2007 Sep 15;110(6):2049-56. doi: 10.1182/blood-2007-01-066803. Epub 2007 May 29.
7
Targeted alpha-particle immunotherapy for acute myeloid leukemia.靶向α粒子免疫疗法治疗急性髓系白血病
Am Soc Clin Oncol Educ Book. 2014:e126-31. doi: 10.14694/EdBook_AM.2014.34.e126.
8
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.重组人源化抗CD33抗体的α发射型铋环己基苄基二乙三胺五乙酸构建体:药代动力学、生物活性、毒性及化学性质
J Nucl Med. 1999 Jan;40(1):166-76.
9
Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.有效的α粒子介导的小鼠白血病放射免疫疗法。
Cancer Res. 1992 Oct 15;52(20):5818-20.
10
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.一种用于前列腺癌放射免疫治疗的发射α粒子的抗体([213Bi]J591)。
Cancer Res. 2000 Nov 1;60(21):6095-100.

引用本文的文献

1
Embracing the Future of Clinical Trials in Radiation Therapy: An NRG Oncology CIRO Technology Retreat Whitepaper on Pioneering Technologies and AI-Driven Solutions.拥抱放射治疗临床试验的未来:一份由NRG肿瘤学CIRO技术务虚会发布的关于开创性技术和人工智能驱动解决方案的白皮书。
Int J Radiat Oncol Biol Phys. 2025 Jun 1;122(2):443-457. doi: 10.1016/j.ijrobp.2025.01.006. Epub 2025 Jan 22.
2
Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma.α 放射栓塞在肝癌动物模型中的初步评价。
PLoS One. 2022 Jan 21;17(1):e0261982. doi: 10.1371/journal.pone.0261982. eCollection 2022.
3
Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer.
用于癌症导向放射性核素治疗的放射性诊断和治疗药剂。
Curr Med Chem. 2020;27(41):7003-7031. doi: 10.2174/0929867327999200727190423.
4
Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植临床前开发的动物模型
ILAR J. 2018 Dec 31;59(3):263-275. doi: 10.1093/ilar/ily006.
5
Functionalized TiO nanoparticles labelled with Ac for targeted alpha radionuclide therapy.用锕标记的功能化二氧化钛纳米颗粒用于靶向α放射性核素治疗。
J Nanopart Res. 2018;20(3):83. doi: 10.1007/s11051-018-4181-y. Epub 2018 Mar 20.
6
Present and Future Prospects of Radiation Therapy Using α-Emitting Nuclides.使用发射α粒子核素的放射治疗的现状与未来展望
Dose Response. 2018 Jan 22;16(1):1559325817747387. doi: 10.1177/1559325817747387. eCollection 2018 Jan-Mar.
7
Targeted and Nontargeted α-Particle Therapies.靶向和非靶向α粒子疗法。
Annu Rev Biomed Eng. 2018 Jun 4;20:73-93. doi: 10.1146/annurev-bioeng-062117-120931. Epub 2018 Jan 18.
8
Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.基于抗体的放射性示踪剂合成与应用中金属离子螯合的化学方面
J Labelled Comp Radiopharm. 2018 Jul;61(9):652-671. doi: 10.1002/jlcr.3590. Epub 2018 Mar 12.
9
Automated cassette-based production of high specific activity [Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.基于自动盒式生产高比活度的[铅]基于肽的治疗诊断放射性药物,用于癌症的影像引导放射性核素治疗。
Appl Radiat Isot. 2017 Sep;127:52-60. doi: 10.1016/j.apradiso.2017.05.006. Epub 2017 May 10.
10
(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.基于砹标记的单克隆CD45抗体的非清髓性预处理用于干细胞基因治疗
Hum Gene Ther. 2015 Jun;26(6):399-406. doi: 10.1089/hum.2015.021.